World Health Organization. Global tuberculosis report 2021. Accessed May 29, 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021
Centers for Disease Control and Prevention. Tuberculosis (TB). Data and statistics. Accessed January 4, 2022. https://www.cdc.gov/tb/statistics/default.htm
Deutsch-Feldman M, Pratt RH, Price SF, et al. Tuberculosis - United States, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(12):409-414.
Hartman-Adams H, Clark K, Juckett G. Update on latent tuberculosis infection [published correction appears in Am Fam Physician. 2014; 90(7): 434]. Am Fam Physician. 2014;89(11):889-896.
Bibbins-Domingo K, Grossman DC, Curry SJ, et al.; US Preventive Services Task Force. Screening for latent tuberculosis infection in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;316(9):962-969.
Centers for Disease Control and Prevention. Core curriculum on tuberculosis: what the clinician should know. 7th ed. 2021. Accessed January 3, 2022. https://www.cdc.gov/tb/education/corecurr/pdf/CoreCurriculumTB-508.pdf
Heartland National TB Center. Screening, diagnosis, and treatment of latent tuberculosis infection (LTBI) in primary care settings. Tips for coding and billing. Accessed January 1, 2022. https://www.heartlandntbc.org/wp-content/uploads/2021/12/Screening_Diagnosis_and_Treatment_of_Latent_Tuberculosis_Infection_LTBI_in_Primary_Care_Settings.pdf
World Health Organization. WHO global lists of high burden countries for tuberculosis (TB), TB/HIV and multidrug/rifampicin-resistant TB (MDR/RR-TB), 2021–2025. Accessed August 23, 2021. https://cdn.who.int/media/docs/default-source/hq-tuberculosis/who_globalhbcliststb_2021-2025_backgrounddocument.pdf?sfvrsn=f6b854c2_9
Cain KP, Benoit SR, Winston CA, et al. Tuberculosis among foreign-born persons in the United States. JAMA. 2008;300(4):405-412.
Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis screening, testing, and treatment of U.S. health care personnel: recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(19):439-443.
Centers for Disease Control and Prevention. Health care personnel (HCP) baseline individual TB risk assessment. Accessed January 8, 2022. https://www.cdc.gov/tb/topic/infectioncontrol/pdf/healthCareSettings-assessment.pdf
Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):e1-e33.
Kendig EL, Kirkpatrick BV, Carter WH, et al. Underreading of the tuberculin skin test reaction. Chest. 1998;113(5):1175-1177.
Yancey JR, Melchert VE. QuantiFERON-TB Gold+ for the diagnosis of Mycobacterium tuberculosis infection. Am Fam Physician. 2021;103(3):177-178.
Zwerling A, Behr MA, Verma A, et al. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011;8(3):e1001012.
Furin J, Cox H, Pai M. Tuberculosis. Lancet. 2019;393(10181):1642-1656.
Centers for Disease Control and Prevention. Tuberculosis (TB). Latent TB infection treatment FAQs for clinicians. June 26, 2018. Accessed January 5, 2022. https://www.cdc.gov/tb/education/FAQforProviders.htm
Sterling TR, Njie G, Zenner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1-11.
Njie GJ, Morris SB, Woodruff RY, et al. Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis. Am J Prev Med. 2018;55(2):244-252.
Sterling TR, Villarino ME, Borisov AS, et al.; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155-2166.
Goswami ND, Gadkowski LB, Piedrahita C, et al. Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health. 2012;12:468.
Eastment MC, McClintock AH, McKinney CM, et al. Factors that influence treatment completion for latent tuberculosis infection. J Am Board Fam Med. 2017;30(4):520-527.
Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440-453.
Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195.
World Health Organization. Tuberculosis and COVID-19. Accessed August 29, 2021. https://www.who.int/teams/global-tuberculosis-programme/covid-19
Dorman SE, Nahid P, Kurbatova EV, et al.; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705-1718.
Zha BS, Nahid P. Treatment of drug-susceptible tuberculosis. Clin Chest Med. 2019;40(4):763-774.
Jerant AF, Bannon M, Rittenhouse S. Identification and management of tuberculosis. Am Fam Physician. 2000;61(9):2667-2678.
Potter B, Rindfleisch K, Kraus CK. Management of active tuberculosis. Am Fam Physician. 2005;72(11):2225-2232.
Inge LD, Wilson JW. Update on the treatment of tuberculosis. Am Fam Physician. 2008;78(4):457-465.
Hauck FR, Neese BH, Panchal AS, et al. Identification and management of latent tuberculosis infection. Am Fam Physician. 2009;79(10):879-886.
- Nolt D, Starke JR. Tuberculosis infection in children and adolescents: testing and treatment. Pediatrics. 2021;148(6):e2021054663.